Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 901–1,000 of 1,029
The Role of Glycemic Control and Variability in Diabetic Retinopathy
Chatziralli, I. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0345-5 · Cited by 41
Recent Insights into the Etiopathogenesis of Diabetic Retinopathy and Its Management
Biswas, A., Choudhury, A. D., Agrawal, S., Bisen, A. C., Sanap, S. N., Verma, S. K., Kumar, M., Mishra, A., Kumar, S., Chauhan, M., et al. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2023.0068 · Cited by 43
CTNet: convolutional transformer network for diabetic retinopathy classification
Bala, R., Sharma, A., & Goel, N. (2023) · Neural Computing and Applications · doi:10.1007/s00521-023-09304-3 · Cited by 42
Plasma Metabolomics Identifies Key Metabolites and Improves Prediction of Diabetic Retinopathy
Yang, S., Liu, R., Xin, Z., Zhu, Z., Chu, J., Zhong, P., Zhu, Z., Shang, X., Huang, W., Zhang, L., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.07.004 · Cited by 42
Fluocinolone Acetonide Intravitreal Implant (Iluvien®)
Sanford, M. (2013) · Drugs · doi:10.1007/s40265-013-0010-x · Cited by 40
“Longer duration of diabetes, higher glycosylated haemoglobin levels (reflecting poor diabetic control) and hypertension were confirmed as risk factors for diabetic retinopathy, while a higher total serum cholesterol level was associated with a higher rate of DMO [2].”
BackgroundAnimal models of diabetic retinopathy: doors to investigate pathogenesis and potential therapeutics
Jo, D. H., Cho, C. S., Kim, J. H., Jun, H. O., & Kim, J. H. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-38 · Cited by 43
“Especially, ME located in the most central area of the retina is called clinically significant ME (CSME) [8].”
BackgroundThe Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?
Gorman, D. M., le Roux, C. W., & Docherty, N. G. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.354 · Cited by 40
Clinical Components of Telemedicine Programs for Diabetic Retinopathy
Horton, M. B., Silva, P. S., Cavallerano, J. D., & Aiello, L. P. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0813-8 · Cited by 44
The prevention and treatment of retinal complications in diabetes
Schorr, S. G., Hammes, H., Müller, U. A., Abholz, H., Landgraf, R., & Bertram, B. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0816 · Cited by 51
Diabetic Retinopathy in Patients with Dyslipidemia: Development and Progression
Jeng, C., Hsieh, Y., Yang, C., Yang, C., Lin, C., & Wang, I. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.05.010 · Cited by 43
for the Individualised Screening for Diabetic Retinopathy (ISDR) Study Group, Eleuteri, A., Fisher, A. C., Broadbent, D. M., García-Fiñana, M., Cheyne, C. P., Wang, A., Stratton, I. M., Gabbay, M., Seddon, D., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4386-0 · Cited by 39
“%) who developed STDR developed it after the time predicted by the model.”
BackgroundInfluentialSelf-citationDexamethasone implant in the management of diabetic macular edema from clinician’s perspective
Urbančič, M., & Topčić, I. G. (2019) · Clinical ophthalmology · doi:10.2147/opth.s206769 · Cited by 42
“The risk factors of DME development are largely similar to those for DR.2,3 Inflammation plays an important role in the pathogenesis of DME.”
BackgroundUpdate on Screening for Sight-Threatening Diabetic Retinopathy
Scanlon, P. H. (2019) · Ophthalmic Research · doi:10.1159/000499539 · Cited by 43
Shimura, M., Kitano, S., Muramatsu, D., Fukushima, H., Takamura, Y., Matsumoto, M., Kokado, M., Kogo, J., Sasaki, M., Morizane, Y., et al. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315199 · Cited by 42
Bek, T. (2020) · Diabetologia · doi:10.1007/s00125-020-05234-0 · Cited by 42
Self-citationCircular RNAs in metabolism and metabolic disorders
Zeng, Y.-Z., Zheng, Z., Liu, F., & Yi, G. (2021) · Obesity Reviews · doi:10.1111/obr.13220 · Cited by 41
Huang, C.-H., Yang, C., Hsieh, Y., Yang, C., Ho, T., & Lai, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-84553-7 · Cited by 41
Artificial intelligence in ophthalmopathy and ultra-wide field image: A survey
Yang, J., Fong, S. J., Wang, H., Hu, Q., Lin, C., Huang, S., Shi, J., Lan, K., Tang, R., Wu, Y., et al. (2021) · Expert Systems with Applications · doi:10.1016/j.eswa.2021.115068 · Cited by 47
Baget‐Bernaldiz, M., Romero‐Aroca, P., Santos-Blanco, E., Navarro-Gil, R., Valls, A., Moreno, A., Rashwan, H. A., & Puig, D. (2021) · Diagnostics · doi:10.3390/diagnostics11081385 · Cited by 43
“Approximately 30% of diabetes patients end up developing some type of diabetic retinopathy (DR) [3,4], which is currently the leading cause of preventable vision loss and blindness in the working-age population [5].”
BackgroundDicarbonyl Stress in Diabetic Vascular Disease
Stratmann, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116186 · Cited by 44
“Diabetic retinopathy (DR) is the most common diabetic microvascular disease, with more than one-third of patients with diabetes being affected [37].”
BackgroundGarcía‐Ramírez, M., Hernández, C., Palomer, X., Vázquez‐Carrera, M., & Simó, R. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0759-3 · Cited by 43
“Diabetic macular edema (DME) is the primary cause of poor visual acuity in diabetic patients [1–3].”
BackgroundPopescu, M., Bogdan, C., Pintea, A., Rugină, D. O., & Ionescu, C. M. L. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s156941 · Cited by 43
“DR was present in nearly all diabetic patients after a certain period, with a higher prevalence in type 1 diabetes.(4) Once diagnosed, DR was directly linked to insufficient metabolic control; the strongest predicting risk factors for retinopathy are HbA1c and glycated albumin.”
BackgroundAlramadan, M. J., Magliano, D. J., Alhamrani, H. A., Alramadan, A. J., Alameer, S. M., Amin, G. M., Alkharras, W. A., Bayaseh, N. A., & Billah, B. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.007 · Cited by 45
“Compared to the global prevalence of diabetic neuropathy (15%) and diabetic retinopathy (27%), this study showed a higher prevalence of these complications among people with T2DM [1,22,23].”
BackgroundInfluentialArtificial intelligence for early detection of diabetes mellitus complications via retinal imaging
Sobhi, N., Sadeghi-Bazargani, Y., Mirzaei, M., Abdollahi, M., Jafarizadeh, A., Pedrammehr, S., Alizadehsani, R., Tan, R.-S., Islam, S. M. S., & Acharya, U. R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01596-7 · Cited by 39
“Globally, 1.4 million patients with DM have severe NPDR and PDR and will require treatment to prevent or slow further vision deterioration [6].”
InfluentialHuang, J., & Zhou, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858972 · Cited by 39
“More than 21 million people around the world were affected by DME (8).”
BackgroundWarwick, A., Curran, K., Hamill, B., Stuart, K. V., Khawaja, A. P., Foster, P. J., Lotery, A. J., Quinn, M. P., Madhusudhan, S., Balaskas, K., et al. (2022) · Eye · doi:10.1038/s41433-022-02298-7 · Cited by 45
Khan, J., & Shaw, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-38229-z · Cited by 45
Risk Factors for Proliferative Diabetic Retinopathy in African Americans with Type 2 Diabetes
Penman, A. D., Hancock, H., Papavasileiou, E., James, M., Idowu, O., Riche, D. M., Fernandez, M., Brauner, S. C., Smith, S. O., Hoadley, S., et al. (2016) · Ophthalmic Epidemiology · doi:10.3109/09286586.2015.1119287 · Cited by 43
Impacto de intervenções educativas na redução das complicações diabéticas: revisão sistemática
Menezes, M. M., Lopes, C. T., & Nogueira, L. D. S. (2016) · Revista Brasileira de Enfermagem · doi:10.1590/0034-7167.2016690422i · Cited by 39
Ogura, Y., Shiraga, F., Terasaki, H., Ohji, M., Ishida, S., Sakamoto, T., Hirakata, A., & Ishibashi, T. (2016) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-016-0481-x · Cited by 40
Aroney, C., Fraser‐Bell, S., Lamoureux, E. L., Gillies, M. C., Lim, L. L., & Fenwick, E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19729 · Cited by 39
“A breakdown of the retinal– blood barrier results in the leakage of plasma and lipids into interstitial layers of the macula, causing the thickening of the fovea and severely compromising central vision.(1,2) The impact of DME on patients’ quality of life is considerable,(3,4) and comparable to that of AMD.”
BackgroundSelf-citationCHIEFARI, E. D., Ventura, V., Capula, C., Randazzo, G., Scorcia, V., Fedele, M., Arcidiacono, B., Nevolo, M. T., Bilotta, F. L., Vitiello, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39429 · Cited by 40
Wu, Y., Ai, P., Ai, Z., & Xu, G. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.078 · Cited by 39
Hao, J., Zhang, H., Yu, J., Chen, X., & Yang, L. (2018) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2018.1450516 · Cited by 40
Rudy, M. D., Ahuja, N. K., & Aaronson, A. J. (2018) · JBJS Reviews · doi:10.2106/jbjs.rvw.17.00146 · Cited by 39
Generative Adversarial Networks (GANs) for Retinal Fundus Image Synthesis
Bellemo, V., Burlina, P., Yong, L., Wong, T. Y., & Ting, D. S. W. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-21074-8_24 · Cited by 47
Self-citationOcular Axial Length and Diabetic Retinopathy: The Kailuan Eye Study
Wang, Q., Wang, Y. X., Wu, S. L., Chen, S., Yan, Y. N., Yang, M. C., Yang, J., Zhou, W. J., Chan, S. Y., Zhang, X. H., et al. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27531 · Cited by 42
“In addition, hyperlipidemia, obesity, and decreased kidney function were found to be risk factors for DR in some study populations.(1,3) Only a few studies addressed the question whether ocular factors in addition to the systemic parameters play a role in the development and stage of DR.”
BackgroundSelf-citationEmerging Concepts in the Treatment of Diabetic Retinopathy
Ellis, M., Lent-Schochet, D., Lo, T., & Yiu, G. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1276-5 · Cited by 40
Potential Biomarkers in Diabetic Retinopathy
Adki, K. M., & Kulkarni, Y. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200217092022 · Cited by 39
Zhou, M., Li, G., Zhu, L., Zhou, H., & Lu, L. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15232 · Cited by 39
Emerging drugs for the treatment of diabetic retinopathy
Striglia, E., Caccioppo, A., Castellino, N., Reibaldi, M., & Porta, M. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1801631 · Cited by 39
Self-citationOcular findings in metabolic syndrome: a review
Lima-Fontes, M., Barata, P., Falcão, M. S., & Carneiro, Â. M. (2020) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000104 · Cited by 45
Chancellor, J. R., Soliman, M. K., Shoults, C. C., Faramawi, M. F., Al-Hindi, H., Kirkland, K. A., Chu, C. J., Yang, Y. C., & Sallam, A. B. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.12.027 · Cited by 39
Euswas, N., Phonnopparat, N., Morasert, K., Thakhampaeng, P., Kaewsanit, A., Mungthin, M., Rangsin, R., & Sakboonyarat, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245801 · Cited by 43
DNA methylation in diabetic retinopathy: pathogenetic role and potential therapeutic targets
Cai, C., Meng, C., He, S., Gu, C., Lhamo, T., Draga, D., Luo, D., & Qiu, Q. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00927-y · Cited by 45
“Hyperlipidemia/obesity Some cross-sectional and longitudinal studies indicate an association between an increased risk of DR and hyperlipidemia/obesity [124, 125].”
BackgroundQuantification of risk factors for diabetic retinopathy progression
Tarasewicz, D., Conell, C. A., Gilliam, L. K., & Melles, R. B. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-02007-6 · Cited by 43
The role of autophagy in the treatment of type II diabetes and its complications: a review
Zhao, X., Bie, L., Pang, D.-R., Li, X., Yang, L., Chen, D., Wang, Y.-R., & Gao, Y. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1228045 · Cited by 41
Ocular surface changes in type II diabetic patients with proliferative diabetic retinopathy.
Gao, Y., Zhang, Y., Ru, Y., Wang, X.-W., Yang, J., Li, C., Wang, H., Li, X., & Li, B. (2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.02.26 · Cited by 39
Zhang, X., Zhao, J., Zhao, T., & Liu, H. (2014) · Endocrine · doi:10.1007/s12020-014-0459-8 · Cited by 44
Self-citationSomatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives
Hernández, C., Simó‐Servat, O., & Simó, R. (2014) · Endocrine · doi:10.1007/s12020-014-0232-z · Cited by 42
Protective effect of a Chinese Medicine formula He-Ying-Qing-Re Formula on diabetic retinopathy
Wang, L., Wang, N., Tan, H., Zhang, Y., & Feng, Y. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.04.031 · Cited by 40
“The prevalence of DR among a pooled of worldwide diabetic population was 34.6%, while proliferative DR (PDR), diabetic macular edema (DME) and vision-threaten DR (VTDR) were 7.0%, 6.8% and 10.2% respectively (Yau et al., 2012).”
BackgroundInfluentialSelf-citationPursuing type 1 diabetes mellitus and related complications through urinary proteomics
Caseiro, A., Barros, A. S., Ferreira, R. M., Padrão, A. I., Aroso, M., Quintaneiro, C., Pereira, A., Marinheiro, R., Vitorino, R. M. P., & Amado, F. M. L. (2013) · Translational research · doi:10.1016/j.trsl.2013.09.005 · Cited by 39
“About one-third of the diabetic population present signs of retinopathy and approximately one-tenth have visionthreatening stages of retinopathy such as diabetic macular edema and proliferative diabetic retinopathy.(9,12) It is, therefore, of great interest to recognize these diabetes-related complications in their ea…”
BackgroundEl-Shazly, S., El-Bradey, M. H., & Tameesh, M. K. (2013) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12182 · Cited by 39
“DMO is the principal cause of visual loss in patients with diabetes, which can occur at any stage of diabetic retinopathy (DR); DMO is characterized by increase vascular permeability and deposition of hard exudates at central retina.(3) The exact pathogenesis of DMO remains controversial; however, vascular endothelial…”
BackgroundSiddiqui, M. K., Kennedy, G., Carr, F., Doney, A. S. F., Pearson, E. R., Morris, A. D., Johnson, T., McLaughlin, M., Williams, R. E., & Palmer, C. N. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4601-7 · Cited by 39
“extrapolation of these results; diabetic retinopathy is more prevalent when duration of type 2 diabetes is longer than 10 years [2].”
BackgroundRizzieri, N., Dall’Asta, L., & Ozoliņš, M. (2024) · Vision · doi:10.3390/vision8030048 · Cited by 41
“DR occurs in 30% to 40% of all diabetic individuals, and the increasing prevalence of diabetes parallels DR [8].”
BackgroundA genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy
McAuley, A. K., Dirani, M., Wang, J. J., Connell, P., Lamoureux, E. L., & Hewitt, A. W. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114560160 · Cited by 38
Self-citationNovelties in Diabetic Retinopathy
Ebneter, A., & Zinkernagel, M. S. (2016) · Endocrine development · doi:10.1159/000439391 · Cited by 38
Thomas, R., Luzio, S. D., North, R. V., Banerjee, S., Zekite, A., Bunce, C., & Owens, D. R. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015024 · Cited by 38
Intravitreal dexamethasone implants for diabetic macular edema
Ríos, A., la Fuente-Rodríguez, P. R.-D., Bonaque‐González, S., López-Gálvez, M., López, V. L., & Romero‐Aroca, P. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.01.14 · Cited by 39
Özsaygılı, C., & Duru, N. (2019) · Retina · doi:10.1097/iae.0000000000002537 · Cited by 38
Genome-wide association study for proliferative diabetic retinopathy in Africans
Liu, C., Chen, G., Bentley, A. R., Doumatey, A. P., Zhou, J., Adeyemo, A., Yang, J., & Rotimi, C. N. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0094-7 · Cited by 42
Li, Y., Fu, J., Yu, N., Wu, Y., & Han, N. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0489 · Cited by 38
“50 In the worldwide, approximately 30.7% of the DR patients is considered to confront with the threat 51 from blindness (Yau et al. 2012).”
BackgroundInfluentialWang, X., Dai, L., Li, S., Kong, H., Sheng, B., & Wu, Q. E. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1764975 · Cited by 42
Rêgo, S., Dutra-Medeiros, M., Soares, F., & Monteiro‐Soares, M. (2020) · Ophthalmologica · doi:10.1159/000512638 · Cited by 42
“DR affects 34.6% of individuals with diabetes [9].”
BackgroundInfluentialRagkousis, A., Kozobolis, V., Kabanarou, S. A., Bontzos, G., Mangouritsas, G., Heliopoulos, I., & Chatziralli, I. (2020) · Seminars in Ophthalmology · doi:10.1080/08820538.2020.1845386 · Cited by 42
Aken, E. V., Favreau, M., Ramboer, E., Denhaerynck, K., MacDonald, K., Abraham, I. L., & Brié, H. (2020) · Clinical ophthalmology · doi:10.2147/opth.s281501 · Cited by 38
“Introduction Diabetic macular edema (DME) is a microvascular complication and one of the major vision-threatening causes in the working-age population affecting approximately 7% of patients with diabetes worldwide.(1) Although, the pathogenesis of DME has not been fully elucidated yet, vascular endothelial growth fact…”
BackgroundThe Risk Factors for Diabetic Retinopathy in a Chinese Population: A Cross-Sectional Study
Sun, Q., Jing, Y., Zhang, B., Gu, T., Meng, R., Sun, J., Zhu, D., & Wang, Y. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5340453 · Cited by 49
“A global meta-analysis reported that nearly one-third of diabetic patients have been diagnosed with diabetic retinopathy [1].”
Association of advanced glycation end products with diabetic retinopathy in type 2 diabetes mellitus
Ying, L., Shen, Y., Zhang, Y., Wang, Y., Liu, Y., Yin, J., Wang, Y., Yin, J., Zhu, W., Bao, Y., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108880 · Cited by 40
Autophagy: A Novel Pharmacological Target in Diabetic Retinopathy
Adornetto, A., Gesualdo, C., Laganà, M. L., Trotta, M. C., Rossi, S., & Russo, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695267 · Cited by 39
“In addition, it has been estimated that more than a third of people with diabetes worldwide have some form of DR and that nearly one in 10 develops forms of DR or complications that are particularly threatening for the sight such as proliferative DR or diabetic macular edema (Yau et al., 2012).”
BackgroundType 2 Diabetes Mellitus in Nepal from 2000 to 2020: A systematic review and meta-analysis
Shrestha, D. B., Budhathoki, P., Sedhai, Y. R., Marahatta, A., Lamichhane, S., Nepal, S., Adhikari, A. R., Poudel, A., Nepal, S., & Atreya, A. (2021) · F1000Research · doi:10.12688/f1000research.53970.1 · Cited by 44
Hyperreflective Dots on OCT as a Predictor of Treatment Outcome in Diabetic Macular Edema
Huang, H., Jansonius, N. M., Chen, H., & Los, L. I. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.020 · Cited by 41
Lu, Z., Miao, J., Dong, J., Zhu, S., Wang, X., & Feng, J. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.104365 · Cited by 38
Santos, F. M., Ciordia, S., Mesquita, J., Sousa, J. P. C., Paradela, A., Tomaz, C. T., & Passarinha, L. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04670-y · Cited by 43
Jiao, W., Ji, J., Li, F., Guo, J., Zheng, Y., Li, S., & Xu, W. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9637 · Cited by 46
“hemorrhage, and proliferative DR, which has been identified by vitreous hemorrhage and neovascularization of the eye fundus and iris (1).”
Backgroundde Gaetano, M., McEvoy, C. M., Andrews, D. C., Cacace, A., Hunter, J., Brennan, E. P., & Godson, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01488 · Cited by 44
“It is currently the leading cause of blindness in the adult working population (Congdon et al., 2004; Yau et al., 2012).”
BackgroundLim, R. R., Vaidya, T. A., Gadde, S. G. K., Yadav, N. K., Sethu, S., Hainsworth, D. P., Mohan, R. R., Ghosh, A., & Chaurasia, S. S. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.03.014 · Cited by 40
Joo, J. H., Sharma, N., Shaia, J., Wu, A. K., Skugor, M., Singh, R. P., & Rachitskaya, A. V. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100547 · Cited by 37
Dascălu, A. M., Şerban, D., Tănăsescu, D., VANCEA, G., Cristea, B. M., Stana, D., Nicolae, V. A., Serboiu, C. S., Tribus, L. C., Tudor, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11082106 · Cited by 40
“The World Health Organization (WHO) Universal Eye Health: A Global Action Plan 2014–2019 outlines the need to achieve a reduction in the prevalence of avoidable visual impairment and blindness, including that related to diabetes, which is currently among the five most common causes of both moderate or severe visual im…”
BackgroundTeleophthalmology and retina: a review of current tools, pathways and services
Than, J., Sim, P. Y., Muttuvelu, D. V., Ferraz, D., Koh, V., Kang, S., & Huemer, J. C. (2023) · International Journal of Retina and Vitreous · doi:10.1186/s40942-023-00502-8 · Cited by 41
“Diabetes mellitus (DM) affects approximately half a billion people worldwide [6], with a third of these suffering from diabetic retinopathy [7].”
BackgroundObesity, body fat distribution and eye diseases
Bosello, F., Vanzo, A., Zaffalon, C., Polinelli, L., Saggin, F., Bonacci, E., Pedrotti, E., Marchini, G., & Bosello, O. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-024-01662-8 · Cited by 41
“…(DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes in a systematic literature review of 35 studies: 34.6% of diabetic patients were affected by any DR, 6.96% by proliferative diabetic retinopathy (PDR), 6.81% by diabetic macular edema, and 10% by VTDR [75].”
BackgroundInfluentialMassin, P., Erginay, A., Dupas, B., Couturier, A., & Tadayoni, R. (2016) · Clinical ophthalmology · doi:10.2147/opth.s105385 · Cited by 37
Ruia, S., Saxena, S., Cheung, C. M. G., Gilhotra, J. S., & Lai, T. Y. Y. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000218 · Cited by 38
“There are approximately 93 million people with DR and 21 million with DME in the world.(2) According to studies on the natural history of DME, 24% of eyes with DME experienced visual loss of at least 3 lines of vision within 3 years.”
BackgroundDiabetics Retinopathy Knowledge and Awareness Assessment among the Type 2 Diabetics
Almalki, N. R., Almalki, T. M., & Alswat, K. A. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.121 · Cited by 37
Xia, F., Sun, J., Jiang, Y., & Li, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26871 · Cited by 38
“DR is a leading cause of visual impairment among working adults worldwide with an estimated prevalence of 93 million people, 28 million of whom have vision‐ threatening retinopathy (Kuo, Wong, & Rotter, 2014; Yau et al., 2012).”
BackgroundEffect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies
Korobelnik, J., Lu, C., Katz, T. A., Dhoot, D. S., Loewenstein, A., Arnold, J. P., & Staurenghi, G. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.015 · Cited by 37
Vascular changes in diabetic retinopathy—a longitudinal study in the Nile rat
Toh, H., Smolentsev, A., Bozadjian, R. V., Keeley, P. W., Lockwood, M. D., Sadjadi, R., Clegg, D., Blodi, B. A., Coffey, P. J., Reese, B. E., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0264-3 · Cited by 39
Optical coherence tomography angiography in diabetes: A review
Battista, M., Borrelli, E., Sacconi, R., Bandello, F. M., & Querques, G. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672119899901 · Cited by 37
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
Wong, W., Chee, C., Bhargava, M., Chai, C., Lin, H. A., Zhao, P., Mangunkusumo, E. A., Naing, T., Yuen, Y. S., Wong, T. Y., et al. (2020) · Journal of Ophthalmology · doi:10.1155/2020/1875860 · Cited by 37
“DME affects 1 in 15 people with diabetes [1] and is the leading cause of blindness in young adults in developed countries [2].”
BackgroundSelf-citationHigh-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases
Betzler, B. K., Rim, T. H., Sabanayagam, C., Cheung, C. M. G., & Cheng, C. (2020) · Biomolecules · doi:10.3390/biom10040645 · Cited by 37
“Risk factors affecting DR onset and progression have been examined extensively, with associations drawn between DR and duration of diabetes, hyperglycaemia, hypertension, high HbA1c and dyslipidaemia [110,115,116].”
BackgroundLi, Y., Yan, Z., Chaudhry, K., & Kazlauskas, A. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.06.004 · Cited by 37
Oliverio, G. W., Ceravolo, I., Bhatti, A., & Trombetta, C. J. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01621-z · Cited by 37
Genome-wide polygenic risk score for retinopathy of type 2 diabetes
Forrest, I. S., Chaudhary, K., Paranjpe, I., Vy, H. M. T., Márquez‐Luna, C., Rocheleau, G., Saha, A., Chan, L., Vleck, T. T. V., Loos, R. J. F., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab067 · Cited by 38
“hyperlipidemia have been reported as risk factors for DR (6,22) and were associated with DR here (all P < 0.”
BackgroundPereira‐Figueiredo, D., Nascimento, A., Cunha-Rodrigues, M. C., Brito, R., & Calaza, K. D. C. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01077-4 · Cited by 41
Diabetic and Retinal Vascular Eye Disease
Le, H.-G., & Shakoor, A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.02.004 · Cited by 37
Relationship between periodontitis and microangiopathy in type 2 diabetes mellitus: a meta‐analysis
Zhang, X., Wang, M., Wang, X., Qu, H., Zhang, R., Gu, J., Wu, Y., Ni, T., Tang, W., & Li, Q. (2021) · Journal of Periodontal Research · doi:10.1111/jre.12916 · Cited by 38
Self-citationSmall Leucine-Rich Proteoglycans (SLRPs) in the Retina
Low, S. W. Y., Connor, T. B., Kassem, I. S., Costakos, D. M., & Chaurasia, S. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147293 · Cited by 43
“7% of adults aged 45–85 years are affected by age-related macular degeneration (AMD) [1], and 93 million people are suffering from diabetic retinopathy (DR) [2] globally.”
BackgroundFort, P. E., Rajendiran, T. M., Soni, T., Byun, J., Shan, Y., Looker, H. C., Nelson, R. G., Kretzler, M., Michailidis, G. C., Roger, J. E., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152109 · Cited by 41
“Diabetic retinopathy (DR) is one the most common and most devastating diabetes complications with an estimated global prevalence of over 380 million (1, 2).”
Sedova, A., Hajdu, D., Datlinger, F., Steiner, I., Neschi, M., Aschauer, J., Gerendas, B. S., Schmidt-Erfurth, U., & Pollreisz, A. (2022) · Eye · doi:10.1038/s41433-021-01912-4 · Cited by 35
“Diabetic retinopathy (DR) is a vision-threatening disease affecting approximately one-third of individuals diagnosed with diabetes mellitus [1].”
BackgroundMunjral, S., Maindarkar, M. A., Ahluwalia, P., Puvvula, A., Jamthikar, A. D., Jujaray, T., Suri, N., Paul, S., Pathak, R., Saba, L., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12051234 · Cited by 43
“Globally, DR affects 93 million people [11,12].”
The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy—Literature Review
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102761 · Cited by 46
“Thus, a large group of DM patients were found to have differently graded DR [15].”
Background
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.